Related references
Note: Only part of the references are listed.Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition
Vylyny Chat et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
The contribution of active and passive mechanisms of 5mC and 5hmC removal in human T lymphocytes is differentiation- and activation-dependent
Lucia Vincenzetti et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2019)
Immune checkpoint inhibitors and non-small-cell lung cancer management: 2018 update
Omar Abdel-Rahman et al.
IMMUNOTHERAPY (2019)
Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis
Hazem El-Osta et al.
IMMUNOTHERAPY (2019)
Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update
Helene Blons et al.
JOURNAL OF THORACIC DISEASE (2019)
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
Sarabjot Pabla et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy
Melvyn T. Chow et al.
IMMUNITY (2019)
Cancer immunoediting and resistance to T cell-based immunotherapy
Jake S. O'Donnell et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity
Volker M. Lauschke et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Epigenetic therapy in immune-oncology
Peter A. Jones et al.
NATURE REVIEWS CANCER (2019)
Foxp1 Negatively Regulates T Follicular Helper Cell Differentiation and Germinal Center Responses by Controlling Cell Migration and CTLA-4
Bi Shi et al.
JOURNAL OF IMMUNOLOGY (2018)
Pharmacoepigenetics and Toxicoepigenetics: Novel Mechanistic Insights and Therapeutic Opportunities
Volker M. Lauschke et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 58 (2018)
Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer
Ming Li et al.
BMC CANCER (2018)
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade
Sachet A. Shukla et al.
CELL (2018)
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
Sarah B. Goldberg et al.
CLINICAL CANCER RESEARCH (2018)
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
Min Yuen Teo et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
Hira Rizvi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Genetic determinants of co-accessible chromatin regions in activated T cells across humans
Rachel E. Gate et al.
NATURE GENETICS (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Immunotherapy Resistance by Inflammation-Induced Dedifferentiation
Arnav Mehta et al.
CANCER DISCOVERY (2018)
Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive Classes
Alexander Solovyov et al.
CELL REPORTS (2018)
The Role of indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy
Lilla Hornyak et al.
FRONTIERS IN IMMUNOLOGY (2018)
Immunity drives TET1 regulation in cancer through NF-κB
Evelyne Collignon et al.
SCIENCE ADVANCES (2018)
Epigenetic Modifications as Biomarkers of Tumor Development, Therapy Response, and Recurrence across the Cancer Care Continuum
Margaret L. Thomas et al.
CANCERS (2018)
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis
Michael Duruisseaux et al.
LANCET RESPIRATORY MEDICINE (2018)
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
Razvan Cristescu et al.
SCIENCE (2018)
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
Jake R. Conway et al.
GENOME MEDICINE (2018)
Enhancing the Anticancer Efficacy of Immunotherapy through Combination with Histone Modification Inhibitors
Wanyu Sun et al.
GENES (2018)
Plharmacogenomic Biomarkers for Improved Drug Therapy- Recent Progress and Future Developments
Volker M. Lauschke et al.
AAPS JOURNAL (2018)
Next generation predictive biomarkers for immune checkpoint inhibition
Yulian Khagi et al.
CANCER AND METASTASIS REVIEWS (2017)
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong et al.
CLINICAL CANCER RESEARCH (2017)
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Stephane Champiat et al.
CLINICAL CANCER RESEARCH (2017)
FOXP1 is a regulator of quiescence in healthy human CD4+ T cells and is constitutively repressed in T cells from patients with lymphoproliferative disorders
Soizic Garaud et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2017)
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Daniel Sanghoon Shin et al.
CANCER DISCOVERY (2017)
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
Valsamo Anagnostou et al.
CANCER DISCOVERY (2017)
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
Xinqi Wu et al.
CANCER IMMUNOLOGY RESEARCH (2017)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang et al.
NATURE (2017)
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Sydney R. Gordon et al.
NATURE (2017)
Integrating liquid biopsies into the management of cancer
Giulia Siravegna et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Jason J. Luke et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity
W. Joost Lesterhuis et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer
Sanja Stevanovic et al.
SCIENCE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
Enfu Hui et al.
SCIENCE (2017)
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
Whijae Roh et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer
Emma Nolan et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy
Sean P. Arlauckas et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Scott Gettinger et al.
CANCER DISCOVERY (2017)
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Jane Goodall et al.
CANCER DISCOVERY (2017)
Promoter methylation of MCAM, ERα and ERβ in serum of early stage prostate cancer patients
Mariana Brait et al.
ONCOTARGET (2017)
Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma
Yago Pico de Coana et al.
ONCOTARGET (2017)
Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
Pornpimol Charoentong et al.
CELL REPORTS (2017)
Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression
Sebastian Marwitz et al.
CLINICAL EPIGENETICS (2017)
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
Jun Zhou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
Vivek Kumar et al.
FRONTIERS IN PHARMACOLOGY (2017)
Diagnostic Accuracy of Methylated SEPT9 for Blood-based Colorectal Cancer Detection: A Systematic Review and Meta-Analysis
Jiayun Nian et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2017)
Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study
Paola Queirolo et al.
FRONTIERS IN IMMUNOLOGY (2017)
A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
Justin M. David et al.
ONCOIMMUNOLOGY (2017)
IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients
Rossana a Tallerico et al.
ONCOIMMUNOLOGY (2017)
Indicators of responsiveness to immune checkpoint inhibitors
Bradley D. Shields et al.
SCIENTIFIC REPORTS (2017)
A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA
Akira Ooki et al.
CLINICAL CANCER RESEARCH (2017)
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz et al.
CELL (2017)
5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers
Wenshuai Li et al.
CELL RESEARCH (2017)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Spencer C. Wei et al.
CELL (2017)
Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy
Glen J. Weiss et al.
CLINICAL CANCER RESEARCH (2017)
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients
M. F. Sanmamed et al.
ANNALS OF ONCOLOGY (2017)
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
Shumei Kato et al.
CLINICAL CANCER RESEARCH (2017)
Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies
Muhammad A. Alvi et al.
BRITISH JOURNAL OF CANCER (2017)
De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation
Hazem E. Ghoneim et al.
CELL (2017)
Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy
Maria L. Ascierto et al.
CLINICAL CANCER RESEARCH (2017)
PD-L1 expressing circulating tumour cells in head and neck cancers
Arutha Kulasinghe et al.
BMC CANCER (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma
J. Zaragoza et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
An epigenetic biomarker combination of PCDH17 and POU4F2 detects bladder cancer accurately by methylation analyses of urine sediment DNA in Han Chinese
Yongqiang Wang et al.
ONCOTARGET (2016)
Coinhibitory Pathways in Immunotherapy for Cancer
Susanne H. Baumeister et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 34 (2016)
Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma
S. Diem et al.
BRITISH JOURNAL OF CANCER (2016)
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao et al.
CELL (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Benjamin Weide et al.
CLINICAL CANCER RESEARCH (2016)
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Alexander Martens et al.
CLINICAL CANCER RESEARCH (2016)
Emerging Opportunities and Challenges in Cancer Immunotherapy
Theresa L. Whiteside et al.
CLINICAL CANCER RESEARCH (2016)
Portraits of TET-mediated DNA hydroxymethylation in cancer
Jana Jeschke et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2016)
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
Bernhard Mlecnik et al.
IMMUNITY (2016)
Whole-genome DNA methylation and hydroxymethylation profiling for HBV-related hepatocellular carcinoma
Chao Ye et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma
Adil I. Daud et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Control of Foxp3 stability through modulation of TET activity
Xiaojing Yue et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
Weijie Ma et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Genetic and Epigenetic Regulation of PD-1 Expression
Alexander P. R. Bally et al.
JOURNAL OF IMMUNOLOGY (2016)
Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients
Teofila Seremet et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Neoantigen landscape dynamics during human melanoma-T cell interactions
Els M. E. Verdegaal et al.
NATURE (2016)
S-2-hydroxyglutarate regulates CD8+ T-lymphocyte fate
Petros A. Tyrakis et al.
NATURE (2016)
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients
Alena Gros et al.
NATURE MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Single base resolution analysis of 5-hydroxymethylcytosine in 188 human genes: implications for hepatic gene expression
Maxim Ivanov et al.
NUCLEIC ACIDS RESEARCH (2016)
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
Kristen E. Pauken et al.
SCIENCE (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Cell-Intrinsic barriers of T Cell-Based Immunotherapy
Hazem E. Ghoneim et al.
TRENDS IN MOLECULAR MEDICINE (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Immunotherapy and Oncogenic Pathways: The PTEN Connection
Naiyer A. Rizvi et al.
CANCER DISCOVERY (2016)
Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer
Ming Shan et al.
ONCOTARGET (2016)
Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells
Matteo Forloni et al.
CELL REPORTS (2016)
Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients
Qiu-Kui Deng et al.
MEDICAL SCIENCE MONITOR (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
T cell Bim levels reflect responses to anti-PD-1 cancer therapy
Roxana S. Dronca et al.
JCI INSIGHT (2016)
Quantitative detection of methylation of FHIT and BRCA1 promoters in the serum of ductal breast cancer patients
Limei Liu et al.
BIO-MEDICAL MATERIALS AND ENGINEERING (2015)
A urine-based methylation signature for risk stratification within low-risk prostate cancer
T. A. Jatkoe et al.
BRITISH JOURNAL OF CANCER (2015)
Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab
Yoshinobu Koguchi et al.
CANCER RESEARCH (2015)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts
David Roulois et al.
CELL (2015)
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B. Chiappinelli et al.
CELL (2015)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
Dalil Hannani et al.
CELL RESEARCH (2015)
Frequency of O6-Methylguanine-DNA Methyltransferase Promoter Methylation in Cytological Samples From Small Cell Lung Cancer
Umberto Miglio et al.
DIAGNOSTIC CYTOPATHOLOGY (2015)
Detection of SNCA and FBN1 Methylation in the Stool as a Biomarker for Colorectal Cancer
Wen-han Li et al.
DISEASE MARKERS (2015)
The Methylcytosine Dioxygenase Tet2 Promotes DNA Demethylation and Activation of Cytokine Gene Expression in T Cells
Kenji Ichiyama et al.
IMMUNITY (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Control of Regulatory T Cell Migration, Function, and Homeostasis
Daniel J. Campbell
JOURNAL OF IMMUNOLOGY (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Dongjun Peng et al.
NATURE (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
DNA methylation secures CD4+ and CD8+ T cell lineage borders
Yongqiang Feng et al.
NATURE IMMUNOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Antagonists of PD-1 and PD-L1 in Cancer Treatment
Evan J. Lipson et al.
SEMINARS IN ONCOLOGY (2015)
Confusing signals: Recent progress in CTLA-4 biology
Lucy S. K. Walker et al.
TRENDS IN IMMUNOLOGY (2015)
Diagnostic and prognostic epigenetic biomarkers in cancer
Pedro Costa-Pinheiro et al.
EPIGENOMICS (2015)
Imaging regulatory T cell dynamics and CTLA4-mediated suppression of T cell priming
Melanie P. Matheu et al.
NATURE COMMUNICATIONS (2015)
Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model
Lei Wang et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab
Serena S. Kwek et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models
A. Covre et al.
ONCOIMMUNOLOGY (2015)
CTLA-4 controls follicular helper T-cell differentiation by regulating the strength of CD28 engagement
Chun Jing Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer
I. Balgkouranidou et al.
BRITISH JOURNAL OF CANCER (2014)
Postoperative Serum Methylation Levels of TAC1 and SEPT9 Are Independent Predictors of Recurrence and Survival of Patients with Colorectal Cancer
CheeKian Tham et al.
CANCER (2014)
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
Ester Simeone et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
New insights into cancer immunoediting and its three component phases elimination, equilibrium and escape
Deepak Mittal et al.
CURRENT OPINION IN IMMUNOLOGY (2014)
Estrogen receptor alpha (ERα) promoter methylation status in tumor and serum DNA in Egyptian breast cancer patients
Hoda A. Hagrass et al.
GENE (2014)
Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer
Li Wang et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2014)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Dissecting the dynamic changes of 5-hydroxymethylcytosine in T-cell development and differentiation
Ageliki Tsagaratou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Tolerance and exhaustion: defining mechanisms of T cell dysfunction
Andrea Schietinger et al.
TRENDS IN IMMUNOLOGY (2014)
Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4+ T cells tolerized by peptide immunotherapy
Rhoanne C. McPherson et al.
ELIFE (2014)
Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade
Evan J. Lipson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
Jerome Galon et al.
IMMUNITY (2013)
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis
Bernd H. Zinselmeyer et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
Rikke B. Holmgaard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Global DNA Methylation Remodeling Accompanies CD8 T Cell Effector Function
Christopher D. Scharer et al.
JOURNAL OF IMMUNOLOGY (2013)
Active Demethylation of the Foxp3 Locus Leads to the Generation of Stable Regulatory T Cells within the Thymus
Aras Toker et al.
JOURNAL OF IMMUNOLOGY (2013)
Oxidative bisulfite sequencing of 5-methylcytosine and 5-hydroxymethylcytosine
Michael J. Booth et al.
NATURE PROTOCOLS (2013)
DNA methylation: roles in mammalian development
Zachary D. Smith et al.
NATURE REVIEWS GENETICS (2013)
TETonic shift: biological roles of TET proteins in DNA demethylation and transcription
William A. Pastor et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2013)
DNA methylation dynamics in health and disease
Yehudit Bergman et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Alterations of immune response of non-small cell lung cancer with Azacytidine
John Wrangle et al.
ONCOTARGET (2013)
Programmed Cell Death 1-Directed Immunotherapy for Enhancing T-Cell Function
Koichi Araki et al.
IMMUNITY AND TOLERANCE (2013)
Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay
Noriaki Yamamoto et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Network Analysis Reveals Centrally Connected Genes and Pathways Involved in CD8+ T Cell Exhaustion versus Memory
Travis A. Doering et al.
IMMUNITY (2012)
Methylation of TMEFF2 gene in tissue and serum DNA from patients with non-small cell lung cancer
Su Man Lee et al.
MOLECULES AND CELLS (2012)
Expression of tumour-specific antigens underlies cancer immunoediting
Michel DuPage et al.
NATURE (2012)
Tet-assisted bisulfite sequencing of 5-hydroxymethylcytosine
Miao Yu et al.
NATURE PROTOCOLS (2012)
DNA methylation profiling in the clinic: applications and challenges
Holger Heyn et al.
NATURE REVIEWS GENETICS (2012)
Tumor Immunotherapy Directed at PD-1
Antoni Ribas
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Analytical sensitivity and stability of DNA methylation testing in stool samples for colorectal cancer detection
Linda J. W. Bosch et al.
CELLULAR ONCOLOGY (2012)
B7-H1 limits the entry of effector CD8+ T cells to the memory pool by upregulating Bim
Rachel M. Gibbons et al.
ONCOIMMUNOLOGY (2012)
Intra-tumour heterogeneity: a looking glass for cancer?
Andriy Marusyk et al.
NATURE REVIEWS CANCER (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
Qing Zhou et al.
BLOOD (2011)
Detection of TFPI2 methylation in the serum of colorectal cancer patients
Kenji Hibi et al.
CANCER LETTERS (2011)
Epigenetic Alteration of DNA in Mucosal Wash Fluid Predicts Invasiveness of Colorectal Tumors
Seiko Kamimae et al.
CANCER PREVENTION RESEARCH (2011)
IL-18 Induces PD-1-Dependent Immunosuppression in Cancer
Magali Terme et al.
CANCER RESEARCH (2011)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity (vol 207, pg 2187, 2010)
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Omid Hamid et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
The biology of cancer testis antigens: Putative function, regulation and therapeutic potential
Elisabetta Fratta et al.
MOLECULAR ONCOLOGY (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia
Oliver Goodyear et al.
BLOOD (2010)
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
Bradley C. Carthon et al.
CLINICAL CANCER RESEARCH (2010)
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients
Julien Fourcade et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Stepwise DNA Methylation Changes Are Linked to Escape from Defined Proliferation Barriers and Mammary Epithelial Cell Immortalization
Petr Novak et al.
CANCER RESEARCH (2009)
Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence
Andreas Herbst et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2009)
Identification and Validation of the Methylated TWIST1 and NID2 Genes through Real-Time Methylation-Specific Polymerase Chain Reaction Assays for the Noninvasive Detection of Primary Bladder Cancer in Urine Samples
Isabelle Renard et al.
EUROPEAN UROLOGY (2009)
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4(+)CD25(Hi) regulatory T cells
Wenshi Wang et al.
INTERNATIONAL IMMUNOLOGY (2009)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal
Brian T. Fife et al.
NATURE IMMUNOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer
Karen Woodson et al.
JOURNAL OF UROLOGY (2008)
Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation
Yasushi Onishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
F. Stephen Hodi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands
M. Campoli et al.
TISSUE ANTIGENS (2008)
Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells
Dafeng Yang et al.
CANCER RESEARCH (2007)
Reversal of the TCR stop signal by CTLA-4
Helga Schneider et al.
SCIENCE (2006)
Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection
Mohammad Obaidul Hoque et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
T-cell tolerance or function is determined by combinatorial costimulatory signals
Roza Nurieva et al.
EMBO JOURNAL (2006)
De novo induction of a cancer/testis antigen by 5-aza-2′-deoxycytidine augments adoptive immunotherapy in a murine tumor model
ZS Guo et al.
CANCER RESEARCH (2006)
PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ
KA Sheppard et al.
FEBS LETTERS (2004)
Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients
MG Friedrich et al.
CLINICAL CANCER RESEARCH (2004)
Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process
D Bruniquel et al.
NATURE IMMUNOLOGY (2003)
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine
T Okazaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
